ReviewDrug design, development and therapy2026
Role of Sodium-Glucose Transport Protein-2 Inhibitors in Renal Protection: A Narrative Review from the Cardiovascular-Kidney-Metabolic Interconnection.
Review in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular-kidney-metabolic (CKM) diseases pose a significant global health burden and are becoming a major healthcare challenge. The intricate interplay among type 2 diabetes mellitus (T2D), cardiovascular disease (CVD) and chronic kidney disease (CKD) has been well established. Therefore, comprehensive management and early intervention are crucial to improving patient outcomes and reducing the strain on medical resources. This narrative review discusses the critical role of renal protection in the context of CKM syndrome, with a focus on the importance of sodium-glucose cotransporter-2 (SGLT-2) inhibitors. These drugs play a significant role in renal protection and in managing a variety of metabolic and cardiovascular disorders or risk factors. Additionally, the review underscores the challenges faced in managing CKM syndrome and suggests potential future directions in China. This reflects a comprehensive approach aimed at enhancing public health strategies in managing the complex interplay among kidney health, cardiovascular function, and metabolic status.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.